Comparison of IV Lignocain and IV Dexmedetomidine for Attenuation of Laryngoscopic Stress Response to Direct Laryngoscopy

Shaheed Mohtarma Benazir Bhutto Institue of Trauma

Status and phase: Completed; Phase 3; Phase 2

Conditions: Hypertension; Tachycardia; Mean Arterial Pressure

Treatments: Drug: Intravenous Dexmedetomidine infusion; Drug: Intravenous Lignocain

Study type: Interventional

Funder types: Other

Identifiers

NCT07385040

ERC-000072/SMBBIT/Aproval/2023

Details and patient eligibility

About

Hemodymanic stress response to direct laryngoscopy and endotracheal intubation is a known phenomenon that occur in almost every patient undergoing general anesthesia before surgical procedure. This response leads to sudden rise in heart rate and blood pressure which may cause serious complications in compromised patients having cardiovascular diseases. There are certain drugs which are used to blunt this response and to prevent the life threatening complications. Intravenous Lignocain is commonly used drug to blunt the laryngoscopic response in our setup. Intravenous Dexmedetomidine is a newer and rarely used drug to prevent stress response to direct laryngoscopy and endotracheal intubation. This study aims to compare the efficacy of both the drugs to provide better control of complications like Arrythmias, stroke and cardiovascular instability.

Enrollment: 62 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients undergoing general anesthesia for any elective surgery Having ASA 1 or 2 Having mallapatti 1 or 2 Having BMI in between 18-30 kg/m2

Exclusion criteria

Lack of consent Anticipated difficult airway Pregnancy Sensitivity to either drug

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

62 participants in 2 patient groups

Group L

Active Comparator group

Description:

Group L received IV Lignocain 1.5mg/kg before induction.

Treatment:

Drug: Intravenous Lignocain

Group D

Active Comparator group

Description:

Group D received IV Dexmedetomidine infusion 10mics/ kg over 10min before induction

Treatment:

Drug: Intravenous Dexmedetomidine infusion